GSK (NYSE:GSK) Announces Quarterly Earnings Results

GSK (NYSE:GSK) issued its quarterly earnings data on Wednesday. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15, Zacks reports. GSK had a return on equity of 50.62% and a net margin of 7.97%. GSK updated its FY 2025 guidance to 2.090-2.130 EPS.

GSK Price Performance

Shares of GSK stock traded up $2.56 during trading on Wednesday, hitting $37.40. The stock had a trading volume of 4,247,405 shares, compared to its average volume of 4,256,092. The business’s 50-day moving average is $34.10 and its 200 day moving average is $37.60. The firm has a market cap of $77.50 billion, a price-to-earnings ratio of 24.28, a P/E/G ratio of 1.38 and a beta of 0.64. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK has a 12 month low of $31.72 and a 12 month high of $45.92.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Finally, Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.